Interested in participating? Learn about a clinical gene therapy study opportunity.
Enh3ance™ Clinical Gene Therapy Phase 3 Study
You are 12 years of age or older
Diagnosis of late-onset OTC deficiency
Will comply with study procedures, requirements, inpatient hospitalizations
Daily treatment with ammonia scavenger(s) medication(s) and/or protein-restricted diet
DTX301 is an investigational gene therapy that is being developed for the treatment of ornithine transcarbamylase (OTC) deficiency. The purpose of this study is to determine the efficacy and confirm the safety of DTX301 in patients 12 years of age and older with late-onset OTC deficiency.
For more information, please visit clinicaltrials.gov
Ultragenyx recognizes that your participation in clinical research has an impact on your (and your loved ones’) time. We may provide compensation and travel support for participation in our clinical trials—the details may vary program to program. You will learn more during the consent process.
All participants will receive DTX301, either on Day 1 or at Week 64 (if still eligible).
All patients who receive DTX301 will be offered enrollment in an optional long-term follow-up study.
Duration
Study visits
You will have lab tests, clinical assessments, and a review of your electronic study diary at inpatient clinic visits and outpatient visits throughout the study.
The number of visits you will have will depend on when you receive DTX301.
Infusion of study and/or placebo medicine into your arm
Health and disease questionnaires
Physical exams and vital signs
Entry and exit interviews
Cognitive tests
Electronic diary entries and reviews*
Blood and urine tests
To learn about current and future studies, you only need to fill out the form once.
*All fields are required.
By submitting this form, you confirm that a diagnosis of OTC has been made by a medical professional.
If you would like to know more about your privacy and the data you submit and data we collect while you are on this website, please see below or visit our privacy policy.
Our Patient Enrollment Liaison (PEL) team will contact you by email or phone within one business day to discuss your study eligibility and answer questions.
If you choose to be contacted by email, be sure to check your spam folder for an email from [email protected], if it’s not in your regular inbox.
Email our PEL team about current and future medical research opportunities.
Patient portrayal.
OTC deficiency is the most common urea cycle disorder and leads to increased levels of ammonia. Patients with OTC deficiency may suffer from acute hyperammonemic episodes that can lead to hospitalization, adverse cognitive and neurological effects, and potentially death.
If you are thinking about joining a study, our Patient Enrollment Liaison (PEL) team is here to help. Every member of our PEL team has a robust professional background and clinical expertise and experience to help answer your questions. Your PEL team member will assist in exploring Ultragenyx clinical and non-interventional clinical trials and related sites where you could be considered for enrollment. Your PEL is here to make the process as easy as possible.
To speak with a PEL about current and future medical research opportunities, please email our PEL team at [email protected].
When you voluntarily submit your personal data, Ultragenyx stores and processes this information in an electronic database consistent with our Privacy Policy. Ultragenyx will use this information to contact you to fulfill your request regarding Ultragenyx research opportunities.
Clinical and nonclinical studies provide invaluable information to treat, diagnose, or discover new breakthroughs in treating rare and ultra-rare diseases. By choosing to participate in research, you may help advance treatments, provide crucial insights, and ultimately improve the quality of life for others living with a rare or ultra-rare disease. You might also benefit from learning more about your condition, gain access to specific care, or achieve faster access to treatment. All efforts of participation, big and small, can make a difference.
Ultragenyx is leading the future of rare disease medicine. We leverage our experience, insight, and commitment to help move the rare disease community forward. Our primary goal is to provide medicines to those with limited options, and to help patients face rare disease head on with courage and confidence.
Ultragenyx is not responsible for the content or privacy policies of third-party websites outside of its control. Content from Ultragenyx Patient Advocacy (ultrarareadvocacy.com) is intended for a U.S. patient and caregiver audience. Content from the Ultragenyx corporate website (ultragenyx.com) is intended for investors and the general public within the U.S. The information provided on these Ultragenyx sites may not apply to your country. Please contact your physician to learn more about these topics. Thank you for visiting our Clinical Trial site. We hope your visit was informative and enjoyable.
Do you wish to continue?